<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38976351</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Evaluating the Application of Nail Polish as an Ostomy Baseplate: A Comparative Analysis With Conventional Ostomy Pastes in the Market and a Clinical Trial.</ArticleTitle><Pagination><StartPage>1332</StartPage><EndPage>1340</EndPage><MedlinePgn>1332-1340</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003446</ELocationID><Abstract><AbstractText Label="BACKGROUND">Peristomal skin complications are prevalent among patients with ostomies and significantly impact their quality of life. Ostomy care is crucial for patients with ostomies because it ensures proper adhesion and protects and reduces the peristomal skin complications.</AbstractText><AbstractText Label="OBJECTIVES">To assess the effectiveness of nail polish as a novel skin barrier and compare its performance with the commonly available ostomy barriers in the market.</AbstractText><AbstractText Label="DESIGN">Phase I randomized controlled trial.</AbstractText><AbstractText Label="SETTINGS">A single trauma and surgery center.</AbstractText><AbstractText Label="PATIENTS">Forty patients who were hospitalized for ostomy implantation were enrolled. Twenty cases were included in each group.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">The use of nail polish as a baseplate was tested against the common ostomy pastes. Over 6 months, the study enrolled 40 patients who required loop ileostomy and were followed up for 8 weeks. Postoperative evaluation was performed using the City of Hope-Quality of Life ostomy and 36-Item Short Form questionnaires, as well as physical examinations conducted 1 day after surgery and at 4 and 8 weeks after surgical treatment.</AbstractText><AbstractText Label="RESULTS">Forty patients were included in the study. At all 3 time points, significant differences were observed in 36-Item Short Form scores, time, and costs spent on ostomy care. The intervention group experienced fewer peristomal skin complications (skin itching, redness, inflammation, and burning) and skin allergies at the first and second time points (p &lt; 0.05). Furthermore, none of the patients in the intervention or control group experienced rare complications such as folliculitis, candidiasis, contact dermatitis, or pyoderma gangrenosum.</AbstractText><AbstractText Label="LIMITATIONS">Single institution.</AbstractText><AbstractText Label="CONCLUSIONS">The utilization of nail polish as a baseplate reduces skin allergies, peristomal skin complications, and the time and financial resources spent on ostomy care. Furthermore, using nail polish has demonstrated promising results in patients' quality of life. Consequently, using nail polish emerged as the preferred choice among study participants. See the Video Abstract .</AbstractText><AbstractText Label="EVALUANDO LA APLICACIN DE ESMALTE DE UAS COMO PLACA BASE DE OSTOMA UN ANLISIS COMPARATIVO CON PASTAS DE OSTOMA CONVENCIONALES EN EL MERCADO EN UN ENSAYO CLNICO">ANTECEDENTES:Las complicaciones de la piel periestomal son frecuentes entre los pacientes con ostom&#xed;as y afectan significativamente su calidad de vida. Los cuidados de la ostom&#xed;a son cruciales para los pacientes ostomizados, ya que garantizan una adhesi&#xf3;n adecuada y protegen y reducen las complicaciones de la piel periestomal.OBJETIVOS:Evaluar la eficacia del esmalte de u&#xf1;as como nueva barrera cut&#xe1;nea y comparar su rendimiento con las barreras de ostom&#xed;a com&#xfa;nmente disponibles en el mercado.DISE&#xd1;O:Ensayo cl&#xed;nico aleatorizado de fase I.ENTORNO:Un &#xfa;nico centro de traumatolog&#xed;a y cirug&#xed;a.PACIENTES:Se incluyeron cuarenta pacientes hospitalizados para la implantaci&#xf3;n de una ostom&#xed;a. Se incluyeron veinte casos en cada grupo.MEDIDAS DE RESULTADO PRINCIPALES:Se prob&#xf3; el uso de esmalte de u&#xf1;as como placa base frente a las pastas de ostom&#xed;a comunes. Durante un periodo de 6 meses, el estudio incluy&#xf3; a 40 pacientes que necesitaban una ileostom&#xed;a en asa y fueron sometidos a un seguimiento de 8 semanas. La evaluaci&#xf3;n postoperatoria se llev&#xf3; a cabo mediante los cuestionarios City of Hope-quality of life ostomy y SF-36, as&#xed; como mediante ex&#xe1;menes f&#xed;sicos realizados 1 d&#xed;a despu&#xe9;s de la cirug&#xed;a y a las 4 y 8 semanas del tratamiento quir&#xfa;rgico.RESULTADOS:Se incluyeron en el estudio cuarenta pacientes. En los 3 puntos temporales, se observaron diferencias significativas en las puntuaciones SF-36, el tiempo y los costos dedicados al cuidado de la ostom&#xed;a. El grupo de intervenci&#xf3;n experiment&#xf3; menos complicaciones cut&#xe1;neas periestomales (picor, enrojecimiento, inflamaci&#xf3;n y quemaz&#xf3;n de la piel), as&#xed; como alergias cut&#xe1;neas en el primer y segundo momento (p &lt; 0,05). Adem&#xe1;s, ninguno de los pacientes del grupo de intervenci&#xf3;n ni del de control experiment&#xf3; complicaciones poco frecuentes como foliculitis, candidiasis, dermatitis de contacto o pioderma gangrenoso.LIMITACIONES:Una sola instituci&#xf3;n.CONCLUSI&#xd3;N:La utilizaci&#xf3;n de esmalte de u&#xf1;as como placa base reduce las alergias cut&#xe1;neas, las complicaciones cut&#xe1;neas periestomales y el tiempo y los recursos econ&#xf3;micos dedicados al cuidado de la ostom&#xed;a. Adem&#xe1;s, el uso de esmalte de u&#xf1;as ha demostrado resultados prometedores en la calidad de vida de los pacientes. En consecuencia, la utilizaci&#xf3;n de esmalte de u&#xf1;as result&#xf3; ser la opci&#xf3;n preferida entre los participantes en el estudio. (Traducci&#xf3;n-Dr. Aurian Garcia Gonzalez).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chinisaz</LastName><ForeName>Fatemeh</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miratashi Yazdi</LastName><ForeName>Seyed Amir</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0003-2274-5727</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmadi Amoli</LastName><ForeName>Hadi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Sina Trauma and Surgery Research Center, Sina Hospital, Tehran University of Medical Science, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sahebi</LastName><ForeName>Leyla</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Maternal, Fetal and Neonatal Research Center, Family Health Research Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007081" MajorTopicYN="Y">Ileostomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010030" MajorTopicYN="N">Ostomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>9</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>8</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>8</Day><Hour>12</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38976351</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003446</ArticleId><ArticleId IdType="pii">00003453-202410000-00018</ArticleId></ArticleIdList><ReferenceList><Title/><Reference><Citation>Malik T, Lee MJ, Harikrishnan AB. The incidence of stoma related morbidity&#x2014;a systematic review of randomised controlled trials. Ann R Coll Surg Engl. 2018;100:501&#x2013;508.</Citation></Reference><Reference><Citation>Taneja C, Netsch D, Rolstad BS, Inglese G, Eaves D, Oster G. Risk and economic burden of peristomal skin complications following ostomy surgery. J Wound Ostomy Continence Nurs. 2019;46:143&#x2013;149.</Citation></Reference><Reference><Citation>Boyles A, Hunt S. Care and management of a stoma: maintaining peristomal skin health. Br J Nurs. 2016;25:S14&#x2013;S21.</Citation></Reference><Reference><Citation>S&#xe6;tre R, Gotfredsen JL, Nonboe P, et al. An ostomy baseplate with a skin-protection technology reduces peristomal skin complications: a randomized controlled trial (the ATTRACT study). Br J Dermatol. 2023;188:474&#x2013;481.</Citation></Reference><Reference><Citation>Ala S, Alvandipour M, Saeedi M, Seyedein S, Monajati M, Koulaeinejad N. Evaluation of cholestyramine 15% ointment in relieving pruritus and burning after ileostomy: a randomized, double-blind placebo-controlled clinical trial. J Invest Surg. 2020;33:795&#x2013;802.</Citation></Reference><Reference><Citation>Grant M, Ferrell B, Dean G, Uman G, Chu D, Krouse R. Revision and psychometric testing of the City of Hope Quality of life-ostomy questionnaire. Qual Life Res. 2004;13:1445&#x2013;1457.</Citation></Reference><Reference><Citation>Naseh L, Rafii F, Moghadasi J, Yousefi F. Quality of life and its dimensions in ostomates. J Clin Nurs Midwifery. 2012;1:10&#x2013;22.</Citation></Reference><Reference><Citation>Motamed N, Ayatollahi A, Zare N, Sadeghi Hassanabadi A. Validity and reliability of the Persian translation of the SF-36 version 2 questionnaire. East Mediterr Health J. 2005;11:349&#x2013;357.</Citation></Reference><Reference><Citation>Ware JE Jr. SF-36 health survey update. Spine. 2000;25:3130&#x2013;3139.</Citation></Reference><Reference><Citation>Fellows J, Voegeli D, H&#xe5;kan-Bloch J, Herschend NO, St&#xf8;rling Z. Multinational survey on living with an ostomy: prevalence and impact of peristomal skin complications. Br J Nurs. 2021;30:S22&#x2013;S30.</Citation></Reference><Reference><Citation>Morss-Walton PC, Yi JZ, Gunning ME, McGee JS. Ostomy 101 for dermatologists: managing peristomal skin diseases. Dermatol Ther. 2021;34:e15069.</Citation></Reference><Reference><Citation>Burch J. Peristomal skin care and the use of accessories to promote skin health. Br J Nurs. 2011;20:S4, S6, S8 passim.</Citation></Reference><Reference><Citation>Tam K-W, Lai J-H, Chen H-C, et al. A systematic review and meta-analysis of randomized controlled trials comparing interventions for peristomal skin care. Ostomy Wound Manage. 2014;60:26&#x2013;33.</Citation></Reference><Reference><Citation>Ratliff CR, Scarano KA, Donovan AM, Colwell JC. Descriptive study of peristomal complications. J Wound Ostomy Continence Nurs. 2005;32:33&#x2013;37.</Citation></Reference><Reference><Citation>Taneja C, Netsch D, Rolstad BS, Inglese G, Lamerato L, Oster G. Clinical and economic burden of peristomal skin complications in patients with recent ostomies. J Wound Ostomy Continence Nurs. 2017;44:350&#x2013;357.</Citation></Reference><Reference><Citation>Meisner S, Lehur P-A, Moran B, Martins L, Jemec GBE. Peristomal skin complications are common, expensive, and difficult to manage: a population based cost modeling study. PLoS One. 2012;7:e37813.</Citation></Reference><Reference><Citation>Martins L, Tavernelli K, Sansom W, et al. Strategies to reduce treatment costs of peristomal skin complications. Br J Nurs. 2012;21:1312&#x2013;1315.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38603800</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>7</Issue><PubDate><Year>2024</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Use of Darvadstrocel (Allogenic Stem Cell Therapy) for Crohn's Fistulas in Real Clinical Practice: The National Project to Implement Mesenchymal Stem Cell for the Treatment of Perianal Crohn's Fistula (the PRIME Study).</ArticleTitle><Pagination><StartPage>960</StartPage><EndPage>967</EndPage><MedlinePgn>960-967</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003216</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Perianal fistulas may affect 15% to 50% of patients with Crohn's disease. Treatment is complex, requiring a multidisciplinary approach. Darvadstrocel (allogenic mesenchymal cells obtained from lipoaspirates) was approved in 2018 by the European and Spanish Agencies of Medicines and Medical Products as a treatment for fistulas in Crohn's disease. Recent guidelines from the European Crohn's and Colitis Organisation and Spanish Working Group on Crohn's Disease and Ulcerative Colitis state that darvadstrocel is effective with a favorable safety profile and a strong level of evidence (n&#x2009;=&#x2009;2).</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Presenting real-world effectiveness data for darvadstrocel in a Spanish population.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Observational retrospective cohort study with prospective data gathering.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">The study was conducted at 14 institutions in Spain.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">From November 2019 to April 2022, all patients (n = 73) treated with darvadstrocel in these institutions were included, fulfilling the following criteria: 1) complex fistula/s in a patient with Crohn's disease; 2) failure of conventional and antitumor necrosis factor treatment; and 3) the absence of collections of &gt;2&#x2009;cm confirmed by pelvic MRI at the time of surgery.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Darvadstrocel treatment.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Clinical response (closure of 50% or more of external openings), complete clinical closure (100% of external openings), and radiological closure (no fluid collection &gt;2&#x2009;cm, edema, or inflammation) evaluated 6 months after treatment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Clinical response was observed in 63 patients (86.3%), complete clinical closure in 50 patients (68.5%), and radiological closure in 45 patients (69.2%). Combined clinical and radiological response was observed in 41 patients (63.1%). Not all clinically healed patients had radiological closure, and vice versa. No serious adverse events were reported.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Retrospective nature of the study.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Study results were consistent with those reported in previous clinical trials, real-world efficacy findings from the INSPIRE study (assessing darvadstrocel effectiveness in Europe, Israel, Switzerland, United Kingdom, and Japan), and previously published literature. Darvadstrocel was effective and demonstrated a favorable safety profile when used in normal clinical practice for the treatment of fistulas in Crohn's disease. See Video Abstract .</AbstractText><AbstractText Label="USO DE DARVADSTROCEL TERAPIA CON CLULAS MADRE ALOGNICAS PARA FSTULA EN ENFERMEDAD DE CROHN EN LA PRCTICA CLNICA REAL EL PROYECTO NACIONAL PARA IMPLEMENTAR DE CLULAS MADRE MESENQUIMALES PARA EL TRATAMIENTO DE LA FSTULA DE CROHN PERIANAL EL ESTUDIO PRIME" NlmCategory="UNASSIGNED">ANTECEDENTES:Las f&#xed;stulas perianales pueden afectar entre el 15 y el 50% de los pacientes con enfermedad de Crohn. El tratamiento es complejo y requiere un enfoque multidisciplinario. El darvadstrocel (c&#xe9;lulas mesenquimales alog&#xe9;nicas obtenidas a partir de lipoaspirados) fue aprobado en 2018 por las Agencias Europea y Espa&#xf1;ola de Medicamentos y Productos Sanitarios como tratamiento de las f&#xed;stulas en la EC. Las recientes directrices de la Organizaci&#xf3;n Europea de Crohn y Colitis y del Grupo de Trabajo Espa&#xf1;ol sobre la Enfermedad de Crohn y Colitis Ulcerosa afirman que darvadstrocel es eficaz con un perfil de seguridad favorable y un s&#xf3;lido nivel de evidencia (2).OBJETIVO:Presentar datos de eficacia real de darvadstrocel en poblaci&#xf3;n espa&#xf1;ola.DISE&#xd1;O:Estudio de cohorte retrospectivo observacional con recopilaci&#xf3;n prospectiva de datos.ESCENARIO:14 instituciones.PACIENTES:Desde noviembre de 2019 hasta abril de 2022, se incluyeron todos los pacientes (73) tratados con darvadstrocel en estas instituciones, que cumplieron los siguientes criterios: 1) f&#xed;stula/s compleja/s en un paciente con enfermedad de Crohn; 2) fracaso del tratamiento convencional y anti factor de necrosis tumoral; 3) ausencia de colecciones &gt; 2 cm confirmada por resonancia magn&#xe9;tica p&#xe9;lvica en el momento de la cirug&#xed;a.INTERVENCIONES:Tratamiento con Darvadstrocel.PRINCIPALES MEDIDAS DE RESULTADO:Respuesta cl&#xed;nica (cierre de &#x2265;50% de las aberturas externas), cierre cl&#xed;nico completo (100% de las aberturas externas) y cierre radiol&#xf3;gico (sin acumulaci&#xf3;n de l&#xed;quido &gt;2 cm, sin edema ni inflamaci&#xf3;n) evaluados 6 meses despu&#xe9;s del tratamiento.RESULTADOS:Se observ&#xf3; respuesta cl&#xed;nica en 63 pacientes (86.3%), cierre cl&#xed;nico completo en 50 pacientes (68.5%) y cierre radiol&#xf3;gico en 45 pacientes (69.2%). Se observ&#xf3; respuesta cl&#xed;nica y radiol&#xf3;gica combinada en 41 pacientes (63.1%). No todos los pacientes cl&#xed;nicamente curados tuvieron cierre radiol&#xf3;gico y viceversa. No hubo eventos adversos graves reportados.LIMITACIONES:Estudio retrospectivoCONCLUSIONES:Los resultados del estudio fueron consistentes con los informados en ensayos cl&#xed;nicos anteriores, los hallazgos de eficacia en el mundo real del estudio INSPIRE (que eval&#xfa;a la efectividad de darvadstrocel en Europa, Israel, Suiza, el Reino Unido y Jap&#xf3;n) y la literatura publicada anteriormente. Darvadstrocel fue eficaz y demostr&#xf3; un perfil de seguridad favorable cuando se utiliza en la pr&#xe1;ctica cl&#xed;nica habitual para el tratamiento de f&#xed;stulas en la enfermedad de Crohn. (Traducci&#xf3;n-Dr. Jorge Silva Velazco ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Herreros</LastName><ForeName>Maria Dolores</ForeName><Initials>MD</Initials><Identifier Source="ORCID">0000-0002-1136-4518</Identifier><AffiliationInfo><Affiliation>Department of Surgery, University Hospital Fundaci&#xf3;n Jim&#xe9;nez D&#xed;az, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>New Therapy Laboratory, Instituto de Investigaci&#xf3;n Sanitaria Fundaci&#xf3;n Jim&#xe9;nez D&#xed;az, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramirez</LastName><ForeName>Jose-Manuel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Zaragoza, Zaragoza, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Spanish Multimodal Rehabilitation Group (GERM), Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otero-Pi&#xf1;eiro</LastName><ForeName>Ana M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Surgery, University Hospital Clinic, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;-Gallostra</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Surgery, University Hospital Vall Hebron, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Badiola</LastName><ForeName>Izaskun</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Surgery University Hospital Galdakao-Usansolo, Vizcaya, Pais Vasco, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Enr&#xed;quez-Navascues</LastName><ForeName>Jose M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Surgery, University Hospital Donostia, Biodonostia, San Sebastian, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Millan</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Surgery, University Hospital la Fe, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barreiro</LastName><ForeName>Erica M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Department of Surgery, University Hospital of Pontevedra, Galicia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De La Portilla</LastName><ForeName>Fernando</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Surgery University Hospital Virgen del Rocio, Seville, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su&#xe1;rez Alecha</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Surgery, University Hospital of Navarra, Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Olmo</LastName><ForeName>Damian</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Surgery, University Hospital Fundaci&#xf3;n Jim&#xe9;nez D&#xed;az, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>New Therapy Laboratory, Instituto de Investigaci&#xf3;n Sanitaria Fundaci&#xf3;n Jim&#xe9;nez D&#xed;az, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Surgery Department, Universidad Autonoma de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>National Project to Implement Mesenchymal Stem Cell for the Treatment of Perianal Crohn&#x2019;s Fistula (the PRIME Study) Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT05742100</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003424" MajorTopicYN="Y">Crohn Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012003" MajorTopicYN="Y">Rectal Fistula</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045164" MajorTopicYN="Y">Mesenchymal Stem Cell Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Herreros</LastName><ForeName>Maria Dolores</ForeName><Initials>MD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garc&#xed;a-Olmo</LastName><ForeName>Damian</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guadalajara</LastName><ForeName>Hector</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garcia-Arranz</LastName><ForeName>Mariano</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramirez</LastName><ForeName>Jose-Manuel</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Badiola</LastName><ForeName>Izaskun</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fern&#xe1;ndez Miguel</LastName><ForeName>Tamara</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodr&#xed;guez Lago</LastName><ForeName>Iago</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Portugal Porras</LastName><ForeName>Vicente</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Golda</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galvez</LastName><ForeName>Ana</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ruiz Cerulla</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kreisler</LastName><ForeName>Esther</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Otero</LastName><ForeName>Ana M</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tavares</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pena</LastName><ForeName>Romina</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bravo</LastName><ForeName>Raquel</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Enr&#xed;quez-Navascues</LastName><ForeName>Jose M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Placer</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borda</LastName><ForeName>Nerea</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elorza</LastName><ForeName>Garazi</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Millan</LastName><ForeName>Monica</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez Chicote</LastName><ForeName>Cristina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cholewa</LastName><ForeName>Hanna</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nieto</LastName><ForeName>Marta</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marti</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Espin</LastName><ForeName>Eloi</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borruel</LastName><ForeName>Natalia</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Armario Quiteria Hern&#xe1;ndez</LastName><ForeName>Davis</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abrisqueta</LastName><ForeName>Jes&#xfa;s</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ib&#xe1;&#xf1;ez</LastName><ForeName>Noelia</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montoya</LastName><ForeName>Mariano</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>De La Portilla</LastName><ForeName>Fernando</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>V&#xe1;zquez Monchul</LastName><ForeName>Jorge M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>de la Portilla Le&#xf3;n</LastName><ForeName>Mar&#xed;a</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gomez-Rosado</LastName><ForeName>Juan-Carlos</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Torres-Arcos</LastName><ForeName>Cristina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perez-Sanchez</LastName><ForeName>Asuncion</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arg&#xfc;elles-Arias</LastName><ForeName>Federico</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barreiro</LastName><ForeName>Erica</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez de Los Reyes</LastName><ForeName>Ramon</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sanchez-Guillen</LastName><ForeName>Luis</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alcaide-Quir&#xf3;s</LastName><ForeName>M Jos&#xe9;</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arroyo</LastName><ForeName>Antonio</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>L&#xf3;pez-Rodr&#xed;guez-Arias</LastName><ForeName>Francisco</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suarez Alecha</LastName><ForeName>Javier</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oronoz</LastName><ForeName>Bego&#xf1;a</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rubio</LastName><ForeName>Saioa</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vicu&#xf1;a</LastName><ForeName>Miren</ForeName><Initials>M</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>13</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>11</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>11</Day><Hour>17</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38603800</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003216</ArticleId><ArticleId IdType="pii">00003453-202407000-00014</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Parks AG, Gordon PH, Hardcastle JD. A classification of fistula-in-ano. Br J Surg. 1976;63:1&#x2013;12.</Citation></Reference><Reference><Citation>Vigano C, Losco A, Caprioli F, Basilisco G. Incidence and clinical outcomes of intersphincteric abscesses diagnosed by anal ultrasonography in patients with Crohn&#x2019;s disease. Inflamm Bowel Dis. 2011;17:2102&#x2013;2108.</Citation></Reference><Reference><Citation>Limura E, Giordano P. Modern management of anal fistula. World J Gastroenterol. 2015;21:12&#x2013;20.</Citation></Reference><Reference><Citation>Panes J, Rimola J. Perianal fistulizing Crohn&#x2019;s disease: pathogenesis, diagnosis and therapy. Nat Rev Gastroenterol Hepatol. 2017;14:652&#x2013;664.</Citation></Reference><Reference><Citation>Sainio P. Fistula-in-ano in a defined population. Incidence and epidemiological aspects. Ann Chir Gynaecol. 1984;73:219&#x2013;224.</Citation></Reference><Reference><Citation>Garcia-Olmo D, Van Assche G, Tagarro I, et al. Prevalence of anal fistulas in Europe: systematic literature reviews and population-based database analysis. Adv Ther. 2019;36:3503&#x2013;3518.</Citation></Reference><Reference><Citation>Wasmann KA, de Groof EJ, Stellingwerf ME, et al. Treatment of perianal fistulas in Crohn&#x2019;s disease, seton versus anti-TNF versus surgical closure following anti-TNF [PISA]: a randomised controlled trial. J Crohns Colitis. 2020;14:1049&#x2013;1056.</Citation></Reference><Reference><Citation>Hellers G, Bergstrand O, Ewerth S, Holmstrom B. Occurrence and outcome after primary treatment of anal fistulae in Crohn&#x2019;s disease. Gut. 1980;21:525&#x2013;527.</Citation></Reference><Reference><Citation>Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn&#x2019;s disease in Olmsted County, Minnesota. Gastroenterology. 2002;122:875&#x2013;880.</Citation></Reference><Reference><Citation>Adamina M, Bonovas S, Raine T, et al. ECCO guidelines on therapeutics in Crohn&#x2019;s disease: surgical treatment. J Crohns Colitis. 2020;14:155&#x2013;168.</Citation></Reference><Reference><Citation>Panes J, Garcia-Olmo D, Van Assche G, et al.; ADMIRE CD Study Group Collaborators. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn&#x2019;s disease: a phase 3 randomised, double-blind controlled trial. Lancet. 2016;388:1281&#x2013;1290.</Citation></Reference><Reference><Citation>Schwandner O. Stem cell injection for complex anal fistula in Crohn&#x2019;s disease: a single-center experience. World J Gastroenterol. 2021;27:3643&#x2013;3653.</Citation></Reference><Reference><Citation>Cabalzar-Wondberg D, Turina M, Biedermann L, Rogler G, Schreiner P. Allogeneic expanded adipose-derived mesenchymal stem cell therapy for perianal fistulas in Crohn&#x2019;s disease: a case series. Colorectal Dis. 2021;23:1444&#x2013;1450.</Citation></Reference><Reference><Citation>Herreros MD, Garcia-Arranz M, Guadalajara H, De-La-Quintana P, Garcia-Olmo D; FATT Collaborative Group. Autologous expanded adipose-derived stem cells for the treatment of complex cryptoglandular perianal fistulas: a phase III randomized clinical trial (FATT 1: fistula Advanced Therapy Trial 1) and long-term evaluation. Dis Colon Rectum. 2012;55:762&#x2013;772.</Citation></Reference><Reference><Citation>Garcia-Olmo D, Herreros D, Pascual I, et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum. 2009;52:79&#x2013;86.</Citation></Reference><Reference><Citation>Garcia-Olmo D, Herreros D, De-La-Quintana P, et al. Adipose-derived stem cells in Crohn&#x2019;s rectovaginal fistula. Case Rep Med. 2010;2010:961758.</Citation></Reference><Reference><Citation>Garcia-Arranz M, Herreros MD, Gonzalez-Gomez C, et al. Treatment of Crohn&#x2019;s-related rectovaginal fistula with allogeneic expanded-adipose derived stem cells: a phase I-IIa clinical trial. Stem Cells Transl Med. 2016;5:1441&#x2013;1446.</Citation></Reference><Reference><Citation>Garcia-Olmo D, Garcia-Arranz M, Herreros D. Expanded adipose-derived stem cells for the treatment of complex perianal fistula including Crohn&#x2019;s disease. Expert Opin Biol Ther. 2008;8:1417&#x2013;1423.</Citation></Reference><Reference><Citation>Georgiev-Hristov T, Guadalajara H, Herreros MD, et al. A step-by-step surgical protocol for the treatment of perianal fistula with adipose-derived mesenchymal stem cells. J Gastrointest Surg. 2018;22:2003&#x2013;2012.</Citation></Reference><Reference><Citation>Kamal N, Motwani K, Wellington J, Wong U, Cross RK. Fecal incontinence in inflammatory bowel disease. Crohns Colitis 360. 2021;3:otab013.</Citation></Reference><Reference><Citation>Park SH, Aniwan S, Scott Harmsen W, et al. Update on the natural course of fistulizing perianal Crohn&#x2019;s disease in a population-based cohort. Inflamm Bowel Dis. 2019;25:1054&#x2013;1060.</Citation></Reference><Reference><Citation>Garcia-Olmo D, Garcia-Arranz M, Garcia LG, et al. Autologous stem cell transplantation for treatment of rectovaginal fistula in perianal Crohn&#x2019;s disease: a new cell-based therapy. Int J Colorectal Dis. 2003;18:451&#x2013;454.</Citation></Reference><Reference><Citation>Garcia-Olmo D, Gilaberte I, Binek M, et al. Follow-up study to evaluate the long-term safety and efficacy of darvadstrocel (mesenchymal stem cell treatment) in patients with perianal fistulizing Crohn&#x2019;s disease: ADMIRE-CD phase 3 randomized controlled trial. Dis Colon Rectum. 2022;65:713&#x2013;720.</Citation></Reference><Reference><Citation>Zamora O, Baumgart DC, Faubion W, et al. P603 INSPIRE: 6-month interim analysis from an observational post-marketing registry on the effectiveness and safety of darvadstrocel in patients with Crohn&#x2019;s disease and complex perianal fistulas. J Crohns Colitis. 2022;16:i536&#x2013;i537.</Citation></Reference><Reference><Citation>Borruel N, Mart&#xed; M, Armario D, et al. P297 Treatment of patients with complex perianal Crohn&#x2019;s disease with darvadstrocel: a single-institution real life experience. J Crohns Colitis. 2022;16:i326&#x2013;i327.</Citation></Reference><Reference><Citation>Elorza A, Arzallus T, Izagirre A, et al. P390 Efficacy and safety of mesenchymal stem cell therapy with darvadstrocel for complex perianal fistulizing Crohn&#x2019;s disease: multicentric experience in the Basque Country and Navarre. J Crohns Colitis. 2022;16:i388&#x2013;i388.</Citation></Reference><Reference><Citation>Dawoud C, Widmann KM, Czipin S, et al. Efficacy of cx601 (darvadstrocel) for the treatment of perianal fistulizing Crohn&#x2019;s disease&#x2014;a prospective nationwide multicenter cohort study. Wien Klin Wochenschr. 2023.</Citation></Reference><Reference><Citation>Fathallah N, Siproudhis L, Akaffou M, et al. Allogenic stem cells for Crohn&#x2019;s anal fistulas: treating early improves the deep remission rate. Colorectal Dis. 2023;25:2170&#x2013;2176.</Citation></Reference><Reference><Citation>Fathallah N, Akaffou M, Haouari MA, et al. Deep remission improves the quality of life of patients with Crohn&#x2019;s disease and anoperineal fistula treated with darvadstrocel: results of a French pilot study. Tech Coloproctol. 2023;27:1201&#x2013;1210.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38547350</PMID><DateCompleted><Year>2024</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1876-3405</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>16 Suppl 1</Issue><PubDate><Year>2024</Year><Month>Mar</Month><Day>28</Day></PubDate></JournalIssue><Title>International health</Title><ISOAbbreviation>Int Health</ISOAbbreviation></Journal><ArticleTitle>A pilot study to address the mental health of persons living with lymphatic filariasis in L&#xe9;og&#xe2;ne, Haiti: Implementing a chronic disease self-management program using a stepped-wedge cluster design.</ArticleTitle><Pagination><StartPage>i68</StartPage><EndPage>i77</EndPage><MedlinePgn>i68-i77</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/inthealth/ihae006</ELocationID><Abstract><AbstractText Label="BACKGROUND">Neglected tropical diseases (NTDs) inflict significant comorbid disability on the most vulnerable communities; yet interventions targeting the mental health of affected communities are lacking. A pilot study to assess the effectiveness of a chronic disease self-management program (CDSMP) was introduced to lymphatic filariasis peer support groups in L&#xe9;og&#xe2;ne, Haiti.</AbstractText><AbstractText Label="METHODS">Using a closed-cohort stepped-wedge cluster trial design, Hope Clubs were assigned into Arm 1 (n=118 members) and Arm 2 (n=92). Household surveys, measuring self-rated health, depression, disease self-efficacy, perceived social support, and quality of life, were conducted at baseline (before CDSMP); midpoint (after Arm 1/before Arm 2 completed CDSMP); and endpoint (after CDSMP). Non-Hope Club member patients (n=74) were evaluated at baseline for comparison.</AbstractText><AbstractText Label="RESULTS">Fifty percent of Hope Club members (Arm 1: 48.3%, Arm 2: 52.2%) screened positive for depression at baseline, compared with 36.5% of non-Hope Club members. No statistically significant differences were found in outcome measures between intervention observation periods. At endpoint, depressive illness reduced to 28.7% (Arm 1) and 27.6% (Arm 2).</AbstractText><AbstractText Label="CONCLUSIONS">The intervention was feasible to integrate into Hope Clubs, showed overall positive effects and reduced depressive symptoms. More studies are needed to evaluate the efficacy of implementing CDSMP in the NTD context.</AbstractText><AbstractText Label="CONTEXTE">Les maladies tropicales n&#xe9;glig&#xe9;es (MTN) infligent d'importantes incapacit&#xe9;s comorbides aux communaut&#xe9;s les plus vuln&#xe9;rables; pourtant, les interventions ciblant la sant&#xe9; mentale des communaut&#xe9;s affect&#xe9;es font d&#xe9;faut. Une &#xe9;tude pilote visant &#xe0; &#xe9;valuer l'efficacit&#xe9; d'un programme d'autogestion des maladies chroniques (CDSMP) a &#xe9;t&#xe9; introduite dans des groupes de soutien par les pairs pour la filariose lymphatique &#xe0; L&#xe9;og&#xe2;ne, en Ha&#xef;ti.</AbstractText><AbstractText Label="M&#xc9;THODES">Dans le cadre d'un essai en grappe &#xe0; cohorte ferm&#xe9;e, les clubs Hope ont &#xe9;t&#xe9; r&#xe9;partis entre le bras 1 (n=118 membres) et le bras 2 (n=92). Des enqu&#xea;tes aupr&#xe8;s des m&#xe9;nages, mesurant l'auto-&#xe9;valuation de la sant&#xe9;, la d&#xe9;pression, l'auto-efficacit&#xe9; face &#xe0; la maladie, le soutien social per&#xe7;u et la qualit&#xe9; de vie, ont &#xe9;t&#xe9; men&#xe9;es au d&#xe9;part (avant le CDSMP), &#xe0; mi-parcours (apr&#xe8;s que le bras 1 / avant que le bras 2 ait termin&#xe9; le CDSMP) et &#xe0; la fin (apr&#xe8;s le CDSMP). Les patients non membres du Hope Club (n=74) ont &#xe9;t&#xe9; &#xe9;valu&#xe9;s au d&#xe9;but de l'&#xe9;tude &#xe0; des fins de comparaison.</AbstractText><AbstractText Label="R&#xc9;SULTATS">Cinquante pourcent des membres du Hope Club (bras 1 : 48,3%, bras 2 : 52,2%) ont &#xe9;t&#xe9; d&#xe9;pist&#xe9;s positifs pour la d&#xe9;pression au d&#xe9;but de l'&#xe9;tude, contre 36,5% des non-membres du Hope Club. Aucune diff&#xe9;rence statistiquement significative n'a &#xe9;t&#xe9; constat&#xe9;e dans les mesures des r&#xe9;sultats entre les p&#xe9;riodes d'observation de l'intervention. &#xc0; la fin de l'&#xe9;tude, la maladie d&#xe9;pressive &#xe9;tait r&#xe9;duite &#xe0; 28,7% (bras 1) et 27,6% (bras 2).</AbstractText><AbstractText Label="CONCLUSIONS">L'intervention a pu &#xea;tre int&#xe9;gr&#xe9;e dans les clubs Hope, elle a montr&#xe9; des effets globalement positifs et a permis de r&#xe9;duire les sympt&#xf4;mes d&#xe9;pressifs. D'autres &#xe9;tudes sont n&#xe9;cessaires pour &#xe9;valuer l'efficacit&#xe9; de la mise en &#x153;uvre du CDSMP dans le contexte des MTD.</AbstractText><AbstractText Label="ANTECEDENTES">Las enfermedades tropicales desatendidas (ETDs) infligen una importante discapacidad com&#xf3;rbida a las comunidades m&#xe1;s vulnerables; sin embargo, faltan intervenciones dirigidas a la salud mental de las comunidades afectadas. Se introdujo un estudio piloto para evaluar la eficacia de un programa de autogesti&#xf3;n de enfermedades cr&#xf3;nicas (CDSMP, por sus siglas en ingl&#xe9;s) en grupos de apoyo entre pares de filariasis linf&#xe1;tica en L&#xe9;og&#xe2;ne, Hait&#xed;.</AbstractText><AbstractText Label="M&#xc9;TODOS">Utilizando un dise&#xf1;o de ensayo por conglomerados de cohortes cerradas escalonadas, los Clubes Esperanza fueron asignados al Grupo 1 (n=118 miembros) y al Grupo 2 (n=92). Se realizaron encuestas en los hogares para medir la autoevaluaci&#xf3;n de la salud, la depresi&#xf3;n, la autoeficacia frente a la enfermedad, el apoyo social percibido y la calidad de vida en la l&#xed;nea de base (antes del CDSMP), en el punto medio (despu&#xe9;s de que el Grupo 1/antes de que el Grupo 2 completara el CDSMP) y en el punto final (despu&#xe9;s del CDSMP). Los pacientes que no pertenec&#xed;an al Club Esperanza (n=74) fueron evaluados al inicio del estudio a modo de comparaci&#xf3;n.</AbstractText><AbstractText Label="RESULTADOS">El 50% de los miembros del Club Esperanza (Grupo 1: 48,3%, Grupo 2: 52,2%) dieron positivo en depresi&#xf3;n al inicio del estudio, en comparaci&#xf3;n con el 36,5% de los no miembros del Club Esperanza. No se encontraron diferencias estad&#xed;sticamente significativas en las medidas de resultado entre los periodos de observaci&#xf3;n de la intervenci&#xf3;n. Al final, la enfermedad depresiva se redujo al 28,7% (Grupo 1) y al 27,6% (Grupo 2).</AbstractText><AbstractText Label="CONCLUSIONES">La intervenci&#xf3;n fue factible de integrar en los Clubes Esperanza, mostr&#xf3;efectos positivos generales y redujo los s&#xed;ntomas depresivos. Se necesitan m&#xe1;s estudios para evaluar la eficacia de la aplicaci&#xf3;n del CDSMP en el contexto de las ETD.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2024. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sadiq</LastName><ForeName>Shanze</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Mental Health Program, The Carter Center, Atlanta, GA, 30307, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamre</LastName><ForeName>Karen E S</ForeName><Initials>KES</Initials><AffiliationInfo><Affiliation>Hispaniola Initiative, The Carter Center, Atlanta, GA, 30307, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Samhita</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Mental Health Program, The Carter Center, Atlanta, GA, 30307, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bazur-Leidy</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Mental Health Program, The Carter Center, Atlanta, GA, 30307, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xe9;sir</LastName><ForeName>Lucc&#xe8;ne</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Hispaniola Initiative, The Carter Center, Atlanta, GA, 30307, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xe9;sir</LastName><ForeName>M Martha</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Notre Dame Haiti Program, University of Notre Dame, Port-au-Prince, Haiti.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilbert</LastName><ForeName>Murielle C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>National Program to Eliminate Lymphatic Filariasis, Ministry of Public Health and Population, Port-au-Prince, Haiti.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beau de Rochars</LastName><ForeName>V Madsen</ForeName><Initials>VM</Initials><AffiliationInfo><Affiliation>Hispaniola Initiative, The Carter Center, Atlanta, GA, 30307, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Services Research, Management and Policy, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Telfort</LastName><ForeName>Marc-Aur&#xe8;le</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>National Program to Eliminate Lymphatic Filariasis, Ministry of Public Health and Population, Port-au-Prince, Haiti.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noland</LastName><ForeName>Gregory S</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Hispaniola Initiative, The Carter Center, Atlanta, GA, 30307, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Byrd</LastName><ForeName>Eve</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Mental Health Program, The Carter Center, Atlanta, GA, 30307, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Bill and Melinda Gates Foundation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int Health</MedlineTA><NlmUniqueID>101517095</NlmUniqueID><ISSNLinking>1876-3405</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004605" MajorTopicYN="Y">Elephantiasis, Filarial</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006205" MajorTopicYN="N" Type="Geographic">Haiti</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008603" MajorTopicYN="N">Mental Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073278" MajorTopicYN="Y">Self-Management</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">chronic disease self-management</Keyword><Keyword MajorTopicYN="N">depression</Keyword><Keyword MajorTopicYN="N">lymphatic filariasis</Keyword><Keyword MajorTopicYN="N">mental health</Keyword><Keyword MajorTopicYN="N">neglected tropical diseases</Keyword></KeywordList><CoiStatement>SK is a Guest Editor of this supplement but had no role in the review of this manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>8</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>1</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>28</Day><Hour>18</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>28</Day><Hour>14</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38547350</ArticleId><ArticleId IdType="pmc">PMC10977951</ArticleId><ArticleId IdType="doi">10.1093/inthealth/ihae006</ArticleId><ArticleId IdType="pii">7636814</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
Centers for Disease Control and Prevention . Neglected Tropical Diseases. https://www.cdc.gov/globalhealth/ntd/index.html [accessed 23 September 2022].</Citation></Reference><Reference><Citation>Kuper &#xa0;H. &#xa0;Neglected tropical diseases and disability&#x2014;what is the link? &#xa0;Trans R Soc Trop. 2019;113(12):839&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6903791</ArticleId><ArticleId IdType="pubmed">30892653</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical diseases 2021&#x2013;2030 . Geneva: World Health Organization, 2020.</Citation></Reference><Reference><Citation>Person &#xa0;B, Bartholomew &#xa0;LK, Addiss &#xa0;D, et al. &#xa0;Disrupted social connectedness among Dominican women with chronic filarial lymphedema. Patient Educ Couns. 2007;68(3):279&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">17707609</ArticleId></ArticleIdList></Reference><Reference><Citation>Person &#xa0;B, Bartholomew &#xa0;LK, Gyapong &#xa0;M, et al. &#xa0;Health-related stigma among women with lymphatic filariasis from the Dominican Republic and Ghana. Soc Sci Med. 2009;68(1):30&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">18992982</ArticleId></ArticleIdList></Reference><Reference><Citation>Obindo &#xa0;J, Abdulmalik &#xa0;J, Nwefoh &#xa0;E, et al. &#xa0;Prevalence of depression and associated clinical &#xa0;and socio-demographic factors in people living with lymphatic filariasis in Plateau State, Nigeria. PLOS Negl Trop Dis. 2017;11(6):1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5453421</ArticleId><ArticleId IdType="pubmed">28570585</ArticleId></ArticleIdList></Reference><Reference><Citation>Molyneux &#xa0;DH, Dean &#xa0;L, Adekeye &#xa0;O, et al. &#xa0;The changing global landscape of health and disease: Addressing challenges and opportunities for sustaining progress towards control and elimination of neglected tropical diseases (NTDs). Parasitology. 2018;145(13):1647&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">29547362</ArticleId></ArticleIdList></Reference><Reference><Citation>Ton &#xa0;TGN, Mackenzie &#xa0;C, Molyneux &#xa0;DH. &#xa0;The burden of mental health in lymphatic filariasis. Infect Dis Pov. 2015;4:34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4520254</ArticleId><ArticleId IdType="pubmed">26229599</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Lymphatic filariasis: Managing morbidity and preventing disability: An aide-memoire for national programme managers. World Health Organization. 2013; (1):1&#x2013;67.</Citation></Reference><Reference><Citation>Oscar &#xa0;R, Lemoine &#xa0;JF, Direny &#xa0;AN, et al. &#xa0;Haiti national program for the elimination of lymphatic filariasis-a model of success in the face of adversity. PLoS Negl Trop Dis. 2014;8(7):915.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4102456</ArticleId><ArticleId IdType="pubmed">25032697</ArticleId></ArticleIdList></Reference><Reference><Citation>
The Carter Center . Eliminating malaria from Hispaniola: A binational effort. Summary 2021 Virtual Progra m Review Hispaniola Initiative. https://www.cartercenter.org/resources/pdfs/news/health_publications/hispaniola/2021-carter-center-hispaniola-initiative-proceedings-summary.pdf [accessed 1 May 2023].</Citation></Reference><Reference><Citation>Coreil &#xa0;J, Mayard &#xa0;G, Louis-Charles &#xa0;J, et al. &#xa0;Filarial elephantiasis among Haitian women: Social context and behavioural factors in treatment. Trop Med Int Health. 1998;3(6):467&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">9657509</ArticleId></ArticleIdList></Reference><Reference><Citation>Lammie &#xa0;PJ, Addiss &#xa0;DG, Leonard &#xa0;G, et al. &#xa0;Heterogeneity in filarial-specific immune responsiveness among patients with lymphatic obstruction. J Infect Dis. 1993;167(5):1178&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">8486952</ArticleId></ArticleIdList></Reference><Reference><Citation>Koschorke &#xa0;M, Al-Haboubi &#xa0;YH, Tseng &#xa0;P-C, et al. &#xa0;Mental health, stigma, and neglected tropical diseases: A review and systematic mapping of the evidence. Front Trop Dis. 2022;3:808955.</Citation></Reference><Reference><Citation>van't Noordende &#xa0;AT, Wubie Aycheh &#xa0;M, Tadesse &#xa0;T, et al. &#xa0;A family-based intervention for prevention and self-management of disabilities due to leprosy, podoconiosis and lymphatic filariasis in Ethiopia: A proof of concept study. PLoS Negl Trop Dis. 2021;15(2):e0009167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7924793</ArticleId><ArticleId IdType="pubmed">33600453</ArticleId></ArticleIdList></Reference><Reference><Citation>Dellar &#xa0;R, Ali &#xa0;O, Kinfe &#xa0;M, et al. &#xa0;Effect of a community-based holistic care package on physical and psychosocial outcomes in people with lower limb disorder caused by lymphatic filariasis, podoconiosis, and leprosy in Ethiopia: Results from the EnDPoINT pilot cohort study. Am J Trop Med Hyg. 2022;107(3):624&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9490655</ArticleId><ArticleId IdType="pubmed">35895351</ArticleId></ArticleIdList></Reference><Reference><Citation>Yap &#xa0;JM, Tantono &#xa0;N, Wu &#xa0;VX, Klainin-Yobas P. Effectiveness of technology-based psychosocial interventions on diabetes distress and health-relevant outcomes among type 2 diabetes mellitus: A systematic review and meta-analysis. J Telemed Telecare. 2021;30(2):262&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">34825839</ArticleId></ArticleIdList></Reference><Reference><Citation>Sesel &#xa0;AL, Sharpe &#xa0;L, Naismith &#xa0;SL. &#xa0;Efficacy of psychosocial interventions for people with multiple sclerosis: a meta-analysis of specific treatment effects. Psychother Psychosom. 2018;87(2):105&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">29518781</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorig &#xa0;KR, Sobel &#xa0;DS, Ritter &#xa0;PL, et al. &#xa0;Effect of a self-management program on patients with chronic disease. Eff Clin Pract. 2001;4(6):256&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">11769298</ArticleId></ArticleIdList></Reference><Reference><Citation>Idler &#xa0;EL, Angel &#xa0;RJ. &#xa0;Self-rated health and mortality in the NHANES-I epidemiologic follow-up study. Am J Public Health. 1990;80(4):446&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1404567</ArticleId><ArticleId IdType="pubmed">2316767</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen &#xa0;A, Eustache &#xa0;E, Raviola &#xa0;G, et al. &#xa0;Development and validation of a Haitian creole screening instrument for depression. Transcult Psychiatry. 2015;52:33&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4312265</ArticleId><ArticleId IdType="pubmed">25080426</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimet &#xa0;GD, Dahlem &#xa0;NW, Zimet &#xa0;SG, et al. &#xa0;The Multidimensional scale of perceived social support. J Pers Assess. 1988;52(1):30&#x2013;41.</Citation></Reference><Reference><Citation>Finlay &#xa0;AY, Khan &#xa0;GK. &#xa0;Dermatology Life Quality Index (DLQI)&#x2013;a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">8033378</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritter &#xa0;PL, Ory &#xa0;MG, Laurent &#xa0;DD, et al. &#xa0;Effects of chronic disease self-management programs for participants with higher depression scores: Secondary analyses of an on-line and a small-group program. Transl Behav Med. 2014;4(4):398&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4286546</ArticleId><ArticleId IdType="pubmed">25584089</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim &#xa0;SH, Youn &#xa0;CH. &#xa0;Efficacy of chronic disease self-management program in older Korean adults with low and high health literacy. Asian Nursing Research. 2015;9(1):42&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">25829209</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorig &#xa0;KR, Ritter &#xa0;PL, Pifer &#xa0;C, et al. &#xa0;Effectiveness of the chronic disease self-management program for persons with a serious mental illness: A translation study. Community Ment Health J. 2014;50:96&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">23748554</ArticleId></ArticleIdList></Reference><Reference><Citation>Santini &#xa0;ZI, Koyanagi &#xa0;A, Tyrovolas &#xa0;S, et al. &#xa0;The association between social relationships and depression: A systematic review. J Affect Disord. 2015;175:53&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">25594512</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang &#xa0;B, Xia &#xa0;L, Yu &#xa0;J, et al. &#xa0;The multiple mediating effects of health literacy and self-care confidence between depression and self-care behaviors in patients with heart failure. Heart Lung. 2020;49(6):842&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">33011463</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen &#xa0;HC, Nguyen &#xa0;MH, Do &#xa0;BN, et al. &#xa0;People with suspected COVID-19 symptoms were more likely depressed and had lower health-related quality of life: the potential benefit of health literacy. J Clin Med. 2020;9(4):965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7231234</ArticleId><ArticleId IdType="pubmed">32244415</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas &#xa0;C, Narahari &#xa0;SR, Bose &#xa0;KS, et al. &#xa0;Comparison of three quality of life instruments in lymphatic filariasis: DLQI, WHODAS 2.0, and LFSQQ. PLoS Negl Trop Dis. 2014;8(2):e2716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3930502</ArticleId><ArticleId IdType="pubmed">24587467</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38380823</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Efficacy of Micronized Purified Flavonoid Fraction in the Posthemorrhoidectomy Period Trial: Open-Label Randomized Controlled Trial.</ArticleTitle><Pagination><StartPage>826</StartPage><EndPage>833</EndPage><MedlinePgn>826-833</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003211</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Frequent early postoperative complications of hemorrhoidectomy are thrombosis and edema of mucocutaneous "bridges."</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study aimed to investigate the efficacy of micronized purified flavonoid fraction in preventing complications after elective hemorrhoidectomy.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Prospective unicentral open-label randomized controlled trial.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">2021-2022 at the Clinic of Colorectal and Minimally Invasive Surgery at Sechenov University (Moscow, Russia).</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Patients who underwent hemorrhoidectomy for grade III and IV hemorrhoids.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">After hemorrhoidectomy, patients were randomly assigned either to standard treatment (peroral nonsteroid anti-inflammatory drugs and local anesthetics, topical steroids, psyllium, warm sitz baths, and nifedipine gel), referred to as the control group, or to standard treatment with micronized purified flavonoid fraction, referred to as the study group, and followed up for 60 days.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Thrombosis or edema of mucocutaneous bridges and pain intensity on a visual analog scale &#x43e;n postoperative days 1-7, 14, 21, and 30; quality of life and patient-assessed treatment effect &#x43e;n postoperative days 1, 3, 7, 21, and 30; and perianal skin tags &#x43e;n postoperative day 60.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The data from 50 patients were analyzed (25 in each group). The visual analog scale demonstrated no differences between groups in each follow-up point. Compared to the control group, the patients in the study group had a significantly higher patient-assessed treatment effect &#x43e;n postoperative days 1, 3, 7, 21, and 30 and a significantly lower rate of thrombosis or edema of mucocutaneous bridges &#x43e;n postoperative days 1-7 and 14. Patients in the study group had significantly lower rates of perianal skin tags.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Unicenter open-label design.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Micronized purified flavonoid fraction in the posthemorrhoidectomy period is an effective adjunct to standard treatment that helps reduce the rate of thrombosis and edema of mucocutaneous bridges, improves patient-assessed treatment effect, and prevents postoperative perianal skin tags formation. Micronized purified flavonoid fraction in the posthemorrhoidectomy period is not associated with additional pain relief in comparison with nonmicronized purified flavonoid fraction standard treatment. See Video Abstract .</AbstractText><AbstractText Label="EFICACIA DE LA FRACCIN DE FLAVONOIDES PURIFICADA MICRONIZADA EN EL PERODO POSTERIOR A LA HEMORROIDECTOMA ENSAYO MOST ENSAYO CONTROLADO, ALEATORIZADO, ABIERTO" NlmCategory="UNASSIGNED">ANTECEDENTES:Una complicaci&#xf3;n postoperatoria temprana frecuente de la hemorroidectom&#xed;a es la trombosis y el edema de los "puentes" mucocut&#xe1;neos.OBJETIVO:Investigamos la eficacia de la fracci&#xf3;n de flavonoides purificada micronizada en la prevenci&#xf3;n de complicaciones despu&#xe9;s de una hemorroidectom&#xed;a electiva.DISE&#xd1;O:Ensayo controlado aleatorio, prospectivo, unicentral, abierto.AJUSTES:2021-2022 Cl&#xed;nica de Cirug&#xed;a Colorrectal y M&#xed;nimamente Invasiva Universidad Sechenov (Mosc&#xfa;, Rusia).PACIENTES:Pacientes despu&#xe9;s de hemorroidectom&#xed;a, que se realiz&#xf3; para hemorroides de grado III-IV.INTERVENCIONES:Despu&#xe9;s de la hemorroidectom&#xed;a, los pacientes fueron asignados aleatoriamente al tratamiento est&#xe1;ndar (antiinflamatorios no esteroides perorales y anest&#xe9;sicos locales, esteroides t&#xf3;picos, psyllium, ba&#xf1;os de asiento tibios, gel de nifedipina) - grupo de control, o al tratamiento est&#xe1;ndar con flavonoide purificado micronizado. fracci&#xf3;n (grupo de estudio) y seguido durante 60 d&#xed;as.RESULTADOS DE MEDIDAS PRINCIPALES:Trombosis o edema de puentes mucocut&#xe1;neos e intensidad del dolor en una escala anal&#xf3;gica visual entre el 1.&#xba;, 7.&#xba;, 14.&#xba;, 21.&#xba; y 30.&#xba; d&#xed;a postoperatorio; calidad de vida y efecto del tratamiento evaluado por el paciente el d&#xed;a 1, 3, 7, 21 y 30 del postoperatorio; Marcas cut&#xe1;neas perianales en el d&#xed;a 60 del postoperatorio.RESULTADOS:Se analizaron los datos de 50 pacientes (25 en cada grupo). La escala anal&#xf3;gica visual no demostr&#xf3; diferencias entre grupos en cada punto de seguimiento. En comparaci&#xf3;n con el grupo de control, los pacientes en el grupo de estudio tuvieron un efecto del tratamiento evaluado por el paciente significativamente mayor en los d&#xed;as 1, 3, 7, 21 y 30 despu&#xe9;s de la operaci&#xf3;n, una tasa significativamente menor de trombosis o edema de los puentes mucocut&#xe1;neos en los d&#xed;as 1, 7 y 14.. Los pacientes del grupo de estudio tuvieron tasas significativamente m&#xe1;s bajas de marcas en la piel perianal.LIMITACIONES:Dise&#xf1;o Unicenter de etiqueta abierta.CONCLUSIONES:La fracci&#xf3;n de flavonoides purificada micronizada en el per&#xed;odo posterior a la hemorroidectom&#xed;a es un complemento eficaz del tratamiento est&#xe1;ndar que ayuda a reducir la tasa de trombosis y edema de los puentes mucocut&#xe1;neos, mejora el efecto del tratamiento evaluado por el paciente y previene la formaci&#xf3;n de marcas cut&#xe1;neas perianales posoperatorias. La fracci&#xf3;n de flavonoides purificados micronizados en el per&#xed;odo posterior a la hemorroidectom&#xed;a no se asocia con un alivio adicional del dolor en comparaci&#xf3;n con el tratamiento est&#xe1;ndar con la fracci&#xf3;n de flavonoides purificados no micronizados. (Traducci&#xf3;n-Yesenia Rojas-Khalil ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Medkova</LastName><ForeName>Yuliya Sergeevna</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Clinic of Colorectal and Minimally Invasive Surgery, Sechenov First Moscow State Medical University, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tulina</LastName><ForeName>Inna</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-6404-389</Identifier><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Clinic of Colorectal and Minimally Invasive Surgery, Sechenov First Moscow State Medical University, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yudina</LastName><ForeName>Valeriya</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Clinic of Colorectal and Minimally Invasive Surgery, Sechenov First Moscow State Medical University, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdullaev</LastName><ForeName>Ruslan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Clinic of Colorectal and Minimally Invasive Surgery, Sechenov First Moscow State Medical University, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shcherbakova</LastName><ForeName>Vlada</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Clinic of Colorectal and Minimally Invasive Surgery, Sechenov First Moscow State Medical University, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Novikov</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Heart Rhythm Disorders, Federal State Budget Organization, National Medical Research Center of Cardiology, Ministry of Healthcare of the Russian Federation, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nikonov</LastName><ForeName>Andrey</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Snegirev Clinic of Obstetrics and Gynecology, Sechenov First Moscow State Medical University, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsarkov</LastName><ForeName>Petr</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-7134-6821</Identifier><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Clinic of Colorectal and Minimally Invasive Surgery, Sechenov First Moscow State Medical University, Moscow, Russia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005419">Flavonoids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006484" MajorTopicYN="Y">Hemorrhoids</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005419" MajorTopicYN="Y">Flavonoids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061865" MajorTopicYN="Y">Hemorrhoidectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="Y">Postoperative Complications</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004487" MajorTopicYN="N">Edema</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010149" MajorTopicYN="N">Pain, Postoperative</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="N">Thrombosis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010147" MajorTopicYN="N">Pain Measurement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>3</Day><Hour>18</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>21</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>21</Day><Hour>8</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38380823</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003211</ArticleId><ArticleId IdType="pii">00003453-202406000-00015</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lohsiriwat V. Treatment of hemorrhoids: a coloproctologist&#x2019;s view. World J Gastroenterol. 2015;21:9245&#x2013;9252.</Citation></Reference><Reference><Citation>Du T, Quan S, Dong T, Meng Q. Comparison of surgical procedures implemented in recent years for patients with grade III and IV hemorrhoids: a network meta-analysis. Int J Colorectal Dis. 2019;34:1001&#x2013;1012.</Citation></Reference><Reference><Citation>Simillis C, Thoukididou SN, Slesser AAP, Rasheed S, Tan E, Tekkis PP. Systematic review and network meta-analysis comparing clinical outcomes and effectiveness of surgical treatments for haemorrhoids. Br J Surg. 2015;102:1603&#x2013;1618.</Citation></Reference><Reference><Citation>Aibuedefe B, Kling SM, Philp MM, Ross HM, Poggio JL. An update on surgical treatment of hemorrhoidal disease: a systematic review and meta-analysis. Int J Colorectal Dis. 2021;36:2041&#x2013;2049.</Citation></Reference><Reference><Citation>Davis BR, Lee-Kong SA, Migaly J, Feingold DL, Steele SR. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of hemorrhoids. Dis Colon Rectum. 2018;61:284&#x2013;292.</Citation></Reference><Reference><Citation>Sugimoto T, Tsunoda A, Kano N, Kashiwagura Y, Hirose K-I, Sasaki T. A randomized, prospective, double-blind, placebo-controlled trial of the effect of diltiazem gel on pain after hemorrhoidectomy. World J Surg. 2013;37:2454&#x2013;2457.</Citation></Reference><Reference><Citation>Amoli HA, Notash AY, Shahandashti FJ, Kenari AY, Ashraf H. A randomized, prospective, double-blind, placebo-controlled trial of the effect of topical diltiazem on posthaemorrhoidectomy pain: effect of diltiazem on posthaemorrhoidectomy pain. Colorectal Dis. 2011;13:328&#x2013;332.</Citation></Reference><Reference><Citation>Liu JW, Lin CC, Kiu KT, Wang CY, Tam KW. Effect of glyceryl trinitrate ointment on pain control after hemorrhoidectomy: a meta-analysis of randomized controlled trials. World J Surg. 2016;40:215&#x2013;224.</Citation></Reference><Reference><Citation>Siddiqui MRS, Abraham-Igwe C, Shangumanandan A, Grassi V, Swift I, Abulafi AM. A literature review on the role of chemical sphincterotomy after Milligan&#x2013;Morgan hemorrhoidectomy. Int J Colorectal Dis. 2011;26:685&#x2013;692.</Citation></Reference><Reference><Citation>Hua X, Zhao Y, Zuo H, Liang J. Progress in the treatment of edema after surgery for mixed hemorrhoids. Proc Anticancer Res. 2021;5:102&#x2013;105.</Citation></Reference><Reference><Citation>Tahir M, Rehman MU, Lateef A, et al. Diosmin protects against ethanol-induced hepatic injury via alleviation of inflammation and regulation of TNF-&#x3b1; and NF-&#x3ba;B activation. Alcohol. 2013;47:131&#x2013;139.</Citation></Reference><Reference><Citation>Berk&#xf6;z M. Diosmin suppresses the proinflammatory mediators in lipopolysaccharide-induced RAW264.7 macrophages via NF-&#x3ba;B and MAPKs signal pathways. Gen Physiol Biophys. 2019;38:315&#x2013;324.</Citation></Reference><Reference><Citation>Crespo M, G&#xe1;lvez J, Cruz T, Ocete M, Zarzuelo A. Anti-inflammatory activity of diosmin and hesperidin in rat colitis induced by TNBS. Planta Med. 1999;65:651&#x2013;653.</Citation></Reference><Reference><Citation>Shalkami A, Hassan M, Bakr A. Anti-inflammatory, antioxidant and anti-apoptotic activity of diosmin in acetic acid-induced ulcerative colitis. Hum Exp Toxicol. 2018;37:78&#x2013;86.</Citation></Reference><Reference><Citation>Zieli&#x144;ska-Przyjemska M, Ignatowicz E. Citrus fruit flavonoids influence on neutrophil apoptosis and oxidative metabolism: biological effect of citrus fruit flavonoids. Phytother Res. 2008;22:1557&#x2013;1562.</Citation></Reference><Reference><Citation>Shi X, Liao S, Mi H, et al. Hesperidin prevents retinal and plasma abnormalities in streptozotocin-induced diabetic rats. Molecules. 2012;17:12868&#x2013;12881.</Citation></Reference><Reference><Citation>Qi W, Lin C, Fan K, et al. Hesperidin inhibits synovial cell inflammation and macrophage polarization through suppression of the PI3K/AKT pathway in complete Freund&#x2019;s adjuvant-induced arthritis in mice. Chem Biol Interact. 2019;306:19&#x2013;28.</Citation></Reference><Reference><Citation>Choi IY, Kim SJ, Jeong HJ, et al. Hesperidin inhibits expression of hypoxia inducible factor-1 alpha and inflammatory cytokine production from mast cells. Mol Cell Biochem. 2007;305:153&#x2013;161.</Citation></Reference><Reference><Citation>Orefice R, Litta F, Parello A, et al. A prospective study on the efficacy of two different phlebotonic therapies as a bridge to surgery in patients with advanced hemorrhoidal disease. J Clin Med. 2021;10:1549.</Citation></Reference><Reference><Citation>Godeberge P, Sheikh P, Lohsiriwat V, Jalife A, Shelygin Y. Micronized purified flavonoid fraction in the treatment of hemorrhoidal disease. J Comp Eff Res. 2021;10:801&#x2013;813.</Citation></Reference><Reference><Citation>Alonso-Coello P, Zhou Q, Martinez-Zapata MJ, et al. Meta-analysis of flavonoids for the treatment of haemorrhoids. Br J Surg. 2006;93:909&#x2013;920.</Citation></Reference><Reference><Citation>Rabelo FEF, Lacerda-Filho A, Mansur ES, et al. Benefits of flavonoid and metronidazole use after excisional hemorrhoidectomy: a randomized double-blind clinical trial. Tech Coloproctol. 2021;25:949&#x2013;955.</Citation></Reference><Reference><Citation>La Torre F, Nicolai AP. Clinical use of micronized purified flavonoid fraction for treatment of symptoms after hemorrhoidectomy: results of a randomized, controlled, clinical trial. Dis Colon Rectum. 2004;47:704&#x2013;710.</Citation></Reference><Reference><Citation>Efetov SK, Medkova YS, Kitsenko YE, Ong K, Tulina IA, Tsarkov PV. Step-by-step open excisional haemorrhoidectomy for grade IV circular haemorrhoidal disease&#x2014;a video vignette. Colorectal Dis. 2020;22:1452&#x2013;1453.</Citation></Reference><Reference><Citation>Ware JE, Kosinski M, Keller SDA. 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220&#x2013;233.</Citation></Reference><Reference><Citation>Hoffmann C, McFarland BH, Kinzie JD, et al. Psychometric properties of a Russian version of the SF-12 health survey in a refugee population. Compr Psychiatry. 2005;46:390&#x2013;397.</Citation></Reference><Reference><Citation>Picciariello A, Papagni V, Martines G, De Fazio M, Digennaro R, Altomare DF. Post-operative clinical, manometric, and defecographic findings in patients undergoing unsuccessful STARR operation for obstructed defecation. Int J Colorectal Dis. 2019;34:837&#x2013;842.</Citation></Reference><Reference><Citation>Wang X, Ji X. Sample size estimation in clinical research. Chest. 2020;158:S12&#x2013;S20.</Citation></Reference><Reference><Citation>Perera N, Liolitsa D, Iype S, et al. Phlebotonics for haemorrhoids. Cochrane Database Syst Rev. 2012;8:CD004322.</Citation></Reference><Reference><Citation>Tsarkov P, Medkova Y, Yudina V, et al. The effects of micronized purified flavonoid fraction in post-hemorrhoidectomy period [ASCRS abstract S14]. Dis Colon Rectum. 2023;66:e362&#x2013;e363.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37889999</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Fragility of Statistically Significant Outcomes in Colonic Diverticular Disease Randomized Trials: A Systematic Review.</ArticleTitle><Pagination><StartPage>414</StartPage><EndPage>426</EndPage><MedlinePgn>414-426</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003014</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The p value has been criticized as an oversimplified determination of whether a treatment effect exists. One alternative is the fragility index. It is a representation of the minimum number of nonevents that would need to be converted to events to increase the p value above 0.05.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the fragility index of randomized controlled trials assessing the efficacy of interventions for patients with diverticular disease since 2010 to assess the robustness of current evidence.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">MEDLINE, Embase, and Cochrane Central Register of Controlled Trials were searched from inception to August 2022.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">Articles were eligible for inclusion if they were randomized trials conducted between 2010 and 2022 with parallel, superiority designs evaluating interventions in patients with diverticular disease. Only randomized trials with dichotomous primary outcomes with an associated p value of &lt;0.05 were considered for inclusion.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Any surgical or medical intervention for patients with diverticular disease.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">The fragility index was determined by adding events and subtracting nonevents from the groups with the smaller number of events. Events were added until the p value exceeded 0.05. The smallest number of events required was considered the fragility index.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">After screening 1271 citations, 15 randomized trials met the inclusion criteria. Nine of the studies evaluated surgical interventions and 6 evaluated medical interventions. The mean number of patients randomly assigned and lost to follow-up per randomized controlled trial was 92 (SD 35.3) and 9 (SD 11.4), respectively. The median fragility index was 1 (range, 0-5). The fragility indices for the included studies did not correlate significantly with any study characteristics.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Small sample, heterogeneity, and lack of inclusion of studies with continuous outcomes.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The randomized trials evaluating surgical and medical interventions for diverticular disease are not robust. Changing a single-outcome event in most studies was sufficient to make a statistically significant study finding not significant. See Video Abstract .</AbstractText><AbstractText Label="FRAGILIDAD DE LOS RESULTADOS ESTADSTICAMENTE SIGNIFICATIVOS EN ENSAYOS ALEATORIOS DE ENFERMEDAD DIVERTICULAR DEL COLON UNA REVISIN SISTEMTICA" NlmCategory="UNASSIGNED">ANTECEDENTES:El valor p ha sido criticado por una determinaci&#xf3;n demasiado simplificada de si existe un efecto del tratamiento. Una alternativa es el &#xcd;ndice de Fragilidad. Es una representaci&#xf3;n del n&#xfa;mero m&#xed;nimo de no eventos que deber&#xed;an convertirse en eventos para aumentar el valor p por encima de 0,05.OBJETIVO:Determinar el IF de ensayos controlados aleatorios que eval&#xfa;an la eficacia de las intervenciones para pacientes con enfermedad diverticular desde 2010 para evaluar la solidez de la evidencia actual.FUENTES DE DATOS:Se realizaron b&#xfa;squedas en MEDLINE, Embase y CENTRAL desde el inicio hasta agosto de 2022.SELECCI&#xd3;N DE ESTUDIOS:Los art&#xed;culos eran elegibles para su inclusi&#xf3;n si eran ensayos aleatorizados realizados entre 2010 y 2022 con dise&#xf1;os paralelos de superioridad que evaluaran intervenciones en pacientes con enfermedad diverticular. S&#xf3;lo se consideraron para su inclusi&#xf3;n los ensayos aleatorizados con resultados primarios dicot&#xf3;micos con un valor de p asociado menor que 0,05.INTERVENCI&#xd3;NES:Cualquier intervenci&#xf3;n quir&#xfa;rgica o m&#xe9;dica para pacientes con enfermedad diverticular.PRINCIPALES MEDIDAS DE VALORACI&#xd3;N:El &#xed;ndice de fragilidad se determin&#xf3; sumando eventos y restando no eventos de los grupos con el menor n&#xfa;mero de eventos. Se agregaron eventos hasta que el valor p super&#xf3; 0,05. El menor n&#xfa;mero de eventos requeridos se consider&#xf3; &#xed;ndice de fragilidad.RESULTADOS:Despu&#xe9;s de examinar 1271 citas, 15 ensayos aleatorios cumplieron los criterios de inclusi&#xf3;n. Nueve de los estudios evaluaron intervenciones quir&#xfa;rgicas y seis evaluaron intervenciones m&#xe9;dicas. El n&#xfa;mero medio de pacientes aleatorizados y perdidos durante el seguimiento por ECA fue 92 (DE 35,3) y 9 (DE 11,4), respectivamente. La mediana del &#xed;ndice de fragilidad fue 1 (rango: 0-5). Los &#xed;ndices de fragilidad de los estudios incluidos no se correlacionaron significativamente con ninguna caracter&#xed;stica del estudio.LIMITACIONES:Muestra peque&#xf1;a, heterogeneidad y falta de inclusi&#xf3;n de estudios con resultados continuos.CONCLUSIONES:Los ensayos aleatorios que eval&#xfa;an las intervenciones quir&#xfa;rgicas y m&#xe9;dicas para la enfermedad diverticular no son s&#xf3;lidos. Cambiar un solo evento de resultado en la mayor&#xed;a de los estudios fue suficiente para que un hallazgo estad&#xed;sticamente significativo del estudio no fuera significativo. (Traducci&#xf3;n- Dr. Ingrid Melo ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2023.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McKechnie</LastName><ForeName>Tyler</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of General Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Shuling</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Faculty of Health Sciences, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Kathy</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Faculty of Health Sciences, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Sahil</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of General Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Yung</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of General Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Lily J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Division of General Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Passos</LastName><ForeName>Edward M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Division of General Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doumouras</LastName><ForeName>Aristithes G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Division of General Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of General Surgery, Department of Surgery, St. Joseph Healthcare, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Dennis</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of General Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of General Surgery, Department of Surgery, St. Joseph Healthcare, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parpia</LastName><ForeName>Sameer</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhandari</LastName><ForeName>Mohit</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eskicioglu</LastName><ForeName>Cagla</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-3920-066</Identifier><AffiliationInfo><Affiliation>Division of General Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of General Surgery, Department of Surgery, St. Joseph Healthcare, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="Y">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004241" MajorTopicYN="N">Diverticulum, Colon</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004239" MajorTopicYN="N">Diverticulitis, Colonic</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>27</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>27</Day><Hour>14</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37889999</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003014</ArticleId><ArticleId IdType="pii">00003453-202403000-00012</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>West SG, Duan N, Pequegnat W, et al. Alternatives to the randomized controlled trial. Am J Public Health. 2008;98:1359&#x2013;1366.</Citation></Reference><Reference><Citation>Goodman S. A dirty dozen: twelve P -value misconceptions. Semin Hematol. 2008;45:135&#x2013;140.</Citation></Reference><Reference><Citation>Halsey LG, Curran-Everett D, Vowler SL, Drummond GB. The fickle p value generates irreproducible results. Nat Methods. 2015;12:179&#x2013;185.</Citation></Reference><Reference><Citation>Walsh M, Srinathan SK, McAuley DF, et al. The statistical significance of randomized controlled trial results is frequently fragile: a case for a fragility index. J Clin Epidemiol. 2014;67:622&#x2013;628.</Citation></Reference><Reference><Citation>Wasserstein RL, Lazar NA. The ASA&#x2019;s statement on p -values: context, process, and purpose. Am Stat. 2016;70:129&#x2013;133.</Citation></Reference><Reference><Citation>Chaitoff A, Zheutlin A, Niforatos JD. The fragility index and trial significance. JAMA Intern Med. 2020;180:1554.</Citation></Reference><Reference><Citation>Nelms DW, Vargas HD, Bedi RS, Paruch JL. When the p value doesn&#x2019;t cut it: the fragility index applied to randomized controlled trials in colorectal surgery. Dis Colon Rectum. 2022;65:276&#x2013;283.</Citation></Reference><Reference><Citation>Hall J, Hardiman K, Lee S, et al.; Prepared on behalf of the Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the treatment of left-sided colonic diverticulitis. Dis Colon Rectum. 2020;63:728&#x2013;747.</Citation></Reference><Reference><Citation>Sartelli M, Catena F, Ansaloni L, et al. WSES guidelines for the management of acute left sided colonic diverticulitis in the emergency setting. World J Emerg Surg. 2016;11:1&#x2013;15.</Citation></Reference><Reference><Citation>&#xdc;nl&#xfc; C, de Korte N, Daniels L, et al. A multicenter randomized clinical trial investigating the cost-effectiveness of treatment strategies with or without antibiotics for uncomplicated acute diverticulitis (DIABOLO trial). BMC Surg. 2010;10:1&#x2013;10.</Citation></Reference><Reference><Citation>Bolkenstein H, Consten E, van der Palen J, et al. Long-term outcome of surgery versus conservative management for recurrent and ongoing complaints after an episode of diverticulitis: 5-year follow-up results of a multicenter randomized controlled trial (DIRECT-Trial). Ann Surg. 2019;269:612&#x2013;620.</Citation></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.</Citation></Reference><Reference><Citation>Higgins JPT, Savovic J, Page MJ, Sterne J. Revised Cochrane risk-of-bias tool for randomized trials (RoB 2). In: Higgins JPT, et al, eds. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, UK: Wiley-Blackwell; 2019. https://methods.cochrane.org/bias/resources/rob-2-revised-cochrane-risk-bias-tool-randomized-trials .</Citation></Reference><Reference><Citation>Dettori JR, Norvell DC. How fragile are the results of a trial? The fragility index. Global Spine J. 2020;10:940&#x2013;942.</Citation></Reference><Reference><Citation>Klarenbeek BR, Bergamaschi R, Veenhof AAFA, et al. Laparoscopic versus open sigmoid resection for diverticular disease: follow-up assessment of the randomized control Sigma trial. Surg Endosc. 2011;25:1121&#x2013;1126.</Citation></Reference><Reference><Citation>Lambrichts DPV, Vennix S, Musters GD, et al.; LADIES trial collaborators. Hartmann&#x2019;s procedure versus sigmoidectomy with primary anastomosis for perforated diverticulitis with purulent or faecal peritonitis (LADIES): a multicentre, parallel-group, randomised, open-label, superiority trial. Lancet Gastroenterol Hepatol. 2019;4:599&#x2013;610.</Citation></Reference><Reference><Citation>Mizuki A, Tatemichi M, Nakazawa A, Tsukada N, Nagata H, Kinoshita Y. Effects of Burdock tea on recurrence of colonic diverticulitis and diverticular bleeding: an open-labelled randomized clinical trial. Sci Rep. 2019;9:6793.</Citation></Reference><Reference><Citation>You K, Bendl R, Taut C, Sullivan R, Gachabayov M, Bergamaschi R; Study Group on Diverticulitis. Randomized clinical trial of elective resection versus observation in diverticulitis with extraluminal air or abscess initially managed conservatively. Br J Surg. 2018;105:971&#x2013;979.</Citation></Reference><Reference><Citation>Loire M, Bridoux V, Mege D, et al. Long-term outcomes of Hartmann&#x2019;s procedure versus primary anastomosis for generalized peritonitis due to perforated diverticulitis: follow-up of a prospective multicenter randomized trial (DIVERTI). Int J Colorectal Dis. 2021;36:2159&#x2013;2164.</Citation></Reference><Reference><Citation>Thornell A, Angenete E, Bisgaard T, et al. Laparoscopic lavage for perforated diverticulitis with purulent peritonitis. Ann Intern Med. 2016;164:137&#x2013;145.</Citation></Reference><Reference><Citation>Masoni L, Mari FS, Nigri G, et al. Preservation of the inferior mesenteric artery via laparoscopic sigmoid colectomy performed for diverticular disease: real benefit or technical challenge: a randomized controlled clinical trial. Surg Endosc. 2013;27:199&#x2013;206.</Citation></Reference><Reference><Citation>Edomskis PP, Hoek VT, Stark PW, et al.; LADIES trial collaborators. Hartmann&#x2019;s procedure versus sigmoidectomy with primary anastomosis for perforated diverticulitis with purulent or fecal peritonitis: three-year follow-up of a randomised controlled trial. Int J Surg. 2022;98:106221.</Citation></Reference><Reference><Citation>Schietroma M, Pessia B, Colozzi S, Carlei F, Shehaj I, Amicucci G. Effect of high perioperative oxygen fraction on surgical site infection following surgery for acute sigmoid diverticulitis a prospective, randomized, double blind, controlled, monocentric trial. Chirurgia (Bucur). 2016;111:242&#x2013;250.</Citation></Reference><Reference><Citation>Stollman N, Magowan S, Shanahan F, Quigley EMM; DIVA Investigator Group. A randomized controlled study of mesalamine after acute diverticulitis. J Clin Gastroenterol. 2013;47:621&#x2013;629.</Citation></Reference><Reference><Citation>Kohl A, Rosenberg J, Bock D, et al. Two-year results of the randomized clinical trial DILALA comparing laparoscopic lavage with resection as treatment for perforated diverticulitis. Br J Surg. 2018;105:1128&#x2013;1134.</Citation></Reference><Reference><Citation>Nagata N, Niikura R, Shimbo T, et al. High-dose barium impaction therapy for the recurrence of colonic diverticular bleeding a randomized controlled trial. Ann Surg. 2015;261:269&#x2013;275.</Citation></Reference><Reference><Citation>Lanas A, Ponce J, Bignamini A, Mearin F. One year intermittent rifaximin plus fibre supplementation vs fibre supplementation alone to prevent diverticulitis recurrence: a proof-of-concept study. Dig Liver Dis. 2013;45:104&#x2013;109.</Citation></Reference><Reference><Citation>Tursi A, Brandimarte G, Elisei W, et al. Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease&#x2014;a double-blind, randomised, placebo-controlled study. Aliment Pharmacol Ther. 2013;38:741&#x2013;751.</Citation></Reference><Reference><Citation>Kafka-Ritsch R, Zitt M, Perathoner A, et al. Prospectively randomized controlled trial on damage control surgery for perforated diverticulitis with generalized peritonitis. World J Surg. 2020;44:4098&#x2013;4105.</Citation></Reference><Reference><Citation>Ekhtiari S, Gazendam AM, Nucci NW, Kruse CC, Bhandari M. The fragility of statistically significant findings from randomized controlled trials in hip and knee arthroplasty. J Arthroplasty. 2021;36:2211&#x2013;2218.e1.</Citation></Reference><Reference><Citation>Narayan VM, Gandhi S, Chrouser K, Evaniew N, Dahm P. The fragility of statistically significant findings from randomised controlled trials in the urological literature. BJU Int. 2018;122:160&#x2013;166.</Citation></Reference><Reference><Citation>Pascoal E, Liu M, Lin L, Luketic L. The fragility of statistically significant results in gynaecologic surgery: a systematic review. J Obstet Gynaecol Can. 2022;44:508&#x2013;514.</Citation></Reference><Reference><Citation>Khan M, Evaniew N, Gichuru M, et al. The fragility of statistically significant findings from randomized trials in sports surgery: a systematic survey. Am J Sports Med. 2017;45:2164&#x2013;2170.</Citation></Reference><Reference><Citation>Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2:e124.</Citation></Reference><Reference><Citation>Ioannidis JPA. Contradicted and initially stronger effects in highly cited clinical research. JAMA. 2005;294:218&#x2013;228.</Citation></Reference><Reference><Citation>Colquhoun D. An investigation of the false discovery rate and the misinterpretation of p -values. R Soc Open Sci. 2014;1:140216.</Citation></Reference><Reference><Citation>Thoma A, Farrokhyar F, McKnight L, Bhandari M. How to optimize patient recruitment. Can J Surg. 2010;53:205&#x2013;210.</Citation></Reference><Reference><Citation>Schulz KF, Grimes DA. Sample size calculations in randomised trials: mandatory and mystical. Lancet. 2005;365:1348&#x2013;1353.</Citation></Reference><Reference><Citation>Baer BR, Fremes SE, Gaudino M, Charlson M, Wells MT. On clinical trial fragility due to patients lost to follow up. BMC Med Res Methodol. 2021;21:254.</Citation></Reference><Reference><Citation>Mazzinari G, Ball L, Serpa Neto A, et al. The fragility of statistically significant findings in randomised controlled anaesthesiology trials: systematic review of the medical literature. Br J Anaesth. 2018;120:935&#x2013;941.</Citation></Reference><Reference><Citation>McGlothlin AE, Lewis RJ. Minimal clinically important difference. JAMA. 2014;312:1342&#x2013;1343.</Citation></Reference><Reference><Citation>Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Control Clin Trials. 1989;10:407&#x2013;415.</Citation></Reference><Reference><Citation>Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010; 340:c332&#x2013;c332.</Citation></Reference><Reference><Citation>Khan MS, Fonarow GC, Friede T, et al. Application of the reverse fragility index to statistically nonsignificant randomized clinical trial results. JAMA Netw Open. 2020;3:e2012469.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36940309</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Topical Lidocaine or Lidocaine/Diltiazem Ointment Following Rubber Band Ligation of Hemorrhoids: A Prospective 3-Armed Randomized Controlled Trial.</ArticleTitle><Pagination><StartPage>1110</StartPage><EndPage>1117</EndPage><MedlinePgn>1110-1117</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002774</ELocationID><Abstract><AbstractText Label="BACKGROUND">Rubber band ligation of hemorrhoids causes less pain than excisional hemorrhoidectomy, but many patients still experience significant postprocedure discomfort.</AbstractText><AbstractText Label="OBJECTIVE">This study aimed to determine whether topical lidocaine, with or without diltiazem, is more effective than placebo for analgesia after hemorrhoid banding.</AbstractText><AbstractText Label="DESIGN">This is a prospective, randomized, double-blinded, placebo-controlled trial. Patients were randomly assigned to 2% lidocaine, 2% lidocaine with 2% diltiazem, or a placebo ointment.</AbstractText><AbstractText Label="SETTINGS">This study was performed at 2 university public teaching hospitals and 2 private hospitals in Australia.</AbstractText><AbstractText Label="PATIENTS">Consecutive patients aged &#x2265;18 years undergoing hemorrhoid banding were selected.</AbstractText><AbstractText Label="INTERVENTIONS">Topical ointments were applied postprocedure 3&#xd7; daily for 5 days.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Visual analog pain score, opiate analgesia usage, and patient satisfaction were the main outcome measures.</AbstractText><AbstractText Label="RESULTS">Of 159 eligible patients, 99 were randomly assigned (33 in each group). Pain scores were reduced at 1 hour for the lidocaine (OR 4.15 [1.12-15.41]; p = 0.03) and lidocaine/diltiazem groups (OR 3.85 [1.05-14.11]; p = 0.04) compared with placebo. Patients in the lidocaine/diltiazem group had improved satisfaction (OR 3.82 [1.28-11.44]; p = 0.02) and were more likely to recommend the procedure to others (OR 9.33 [1.07-81.72]; p = 0.04). Patients in the lidocaine/diltiazem group required approximately 45% less total and in-hospital analgesia compared with the placebo. There was no difference in complications between any of the groups.</AbstractText><AbstractText Label="LIMITATIONS">A cost/benefit analysis was not performed. Analgesic efficacy appeared to be short term and the procedures were performed only in the hospital/nonambulatory setting.</AbstractText><AbstractText Label="CONCLUSIONS">Topical lidocaine reduced short-term analgesia use, whereas combination lidocaine/diltiazem was associated with both improved analgesia and patient satisfaction after hemorrhoid banding.</AbstractText><AbstractText Label="LIDOCANA TPICA O UNGENTO DE LIDOCANA/DILTIAZEM DESPUS DE LA LIGADURA HEMORROIDAL CON BANDA ELSTICA UN ENSAYO PROSPECTIVO CONTROLADO Y ALEATORIZADO DE TRES BRAZOS">ANTECEDENTES:La ligadura de hemorroides con banda el&#xe1;stica causa menos dolor que la hemorroidectom&#xed;a escisional, pero muchos pacientes siguen experimentando molestias significativas tras el procedimiento.OBJETIVO:Este estudio tiene como objetivo determinar si la lidoca&#xed;na t&#xf3;pica, con o sin diltiazem, es m&#xe1;s eficaz que el placebo para la analgesia tras la ligadura hemorroidal.DISE&#xd1;O:Este es un ensayo prospectivo, aleatorizado, doble ciego, controlado con placebo. Los pacientes fueron aleatorizados para recibir lidoca&#xed;na al 2 %, lidoca&#xed;na al 2 % con diltiazem al 2 % o ung&#xfc;ento de placebo.AJUSTES:Este estudio se realiz&#xf3; en dos hospitales p&#xfa;blicos con docencia universitaria y dos hospitales privados en Australia.PACIENTES:Se seleccionaron pacientes consecutivos de &#x2265;18 a&#xf1;os sometidos a ligadura para hemorroides.INTERVENCIONES:Se aplicaron ung&#xfc;entos t&#xf3;picos tras el procedimiento tres veces al d&#xed;a durante 5 d&#xed;as.PRINCIPALES MEDIDAS DE RESULTADO:La puntuaci&#xf3;n anal&#xf3;gica visual del dolor, el uso de analg&#xe9;sicos opi&#xe1;ceos y la satisfacci&#xf3;n del paciente fueron las principales medidas de resultado.RESULTADOS:De 159 pacientes elegibles, 99 fueron aleatorizados (33 en cada grupo). Las puntuaciones de dolor se redujeron a la hora para los grupos de lidoca&#xed;na (OR 4,15 (1,12-15,41); p = 0,03) y lidoca&#xed;na/diltiazem (OR 3,85 (1,05-14,11), p = 0,04) en comparaci&#xf3;n con el placebo.Los pacientes del grupo de lidoca&#xed;na/diltiazem mejoraron su satisfacci&#xf3;n (OR 3,82 (1,28-11,44), p = 0,02) y eran m&#xe1;s propensos de recomendar el procedimiento a otros (OR 9,33 (1,07-81,72), p = 0,04). Los pacientes del grupo de lidoca&#xed;na/diltiazem requirieron aproximadamente un 45 % menos de analgesia total e intrahospitalaria en comparaci&#xf3;n con el grupo de placebo. No hubo diferencia en las complicaciones entre ninguno de los grupos.LIMITACIONES:No se realiz&#xf3; un an&#xe1;lisis de costo/beneficio. La eficacia analg&#xe9;sica pareci&#xf3; ser a corto plazo y los procedimientos solo se realizaron en el hospital/entorno no ambulatorio.CONCLUSI&#xd3;N:La lidoca&#xed;na t&#xf3;pica mejora la analgesia a corto plazo, mientras que la combinaci&#xf3;n de lidoca&#xed;na/diltiazem se asocia tanto con una mejor analgesia como con la satisfacci&#xf3;n del paciente tras la colocaci&#xf3;n de bandas para hemorroides. (Traducci&#xf3;n-Dr Osvaldo Gauto ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2023.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kwok</LastName><ForeName>Allan M F</ForeName><Initials>AMF</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, John Hunter Hospital, Waratah, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Stephen R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, John Hunter Hospital, Waratah, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, John Hunter Hospital, Waratah, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carroll</LastName><ForeName>Rosemary</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, John Hunter Hospital, Waratah, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leigh</LastName><ForeName>Lucy</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, John Hunter Hospital, Waratah, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Draganic</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, John Hunter Hospital, Waratah, New South Wales, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EE92BBP03H</RegistryNumber><NameOfSubstance UI="D004110">Diltiazem</NameOfSubstance></Chemical><Chemical><RegistryNumber>98PI200987</RegistryNumber><NameOfSubstance UI="D008012">Lidocaine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009824">Ointments</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004110" MajorTopicYN="Y">Diltiazem</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006484" MajorTopicYN="Y">Hemorrhoids</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006785" MajorTopicYN="N">Hospitals, University</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008012" MajorTopicYN="Y">Lidocaine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009824" MajorTopicYN="N">Ointments</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010146" MajorTopicYN="N">Pain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>20</Day><Hour>14</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36940309</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002774</ArticleId><ArticleId IdType="pii">00003453-202308000-00013</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gallo G, Martellucci J, Sturiale A, et al. Consensus Statement of the Italian Society of Colorectal Surgery (SICCR): management and treatment of hemorrhoidal disease. Tech Coloproctol. 2020;24:145&#x2013;164.</Citation></Reference><Reference><Citation>Albuquerque A. Rubber band ligation of hemorrhoids: a guide for complications. World J Gastrointest Surg. 2016;8:614&#x2013;620.</Citation></Reference><Reference><Citation>Halverson HA. Hemorrhoids. Clin Colon Rectal Surg. 2007;20:77&#x2013;85.</Citation></Reference><Reference><Citation>Linares-Gil MJ, Valls J, Hereu-Boher P, et al. Topical analgesia with lidocaine plus diclofenac decreases pain in benign anorectal surgery: randomized, double-blind, and controlled clinical trial. Clin Transl Gastroenterol. 2018;9:210.</Citation></Reference><Reference><Citation>Hooker GD, Plewes EA, Rajgopal C, Taylor BM. Local injection of bupivacaine after rubber band ligation of hemorrhoids: prospective, randomized study. Dis Colon Rectum. 1999;42:174&#x2013;179.</Citation></Reference><Reference><Citation>Law WL, Chu KW. Triple rubber band ligation for hemorrhoids: prospective, randomized trial of use of local anesthetic injection. Dis Colon Rectum. 1999;42:363&#x2013;366.</Citation></Reference><Reference><Citation>Kwok HC, Noblett SE, Murray NE, Merrie AE, Hayes JL, Bissett IP. The use of local anaesthesia in haemorrhoidal banding: a randomized controlled trial. Colorectal Dis. 2013;15:487&#x2013;491.</Citation></Reference><Reference><Citation>Behrenbruch C, Kong J, Chen F. Local anaesthesia for haemorrhoidal rubber band ligation reduces immediate post-operative recovery time and use of opioid analgesia. ANZ J Surg. 2020;90:576&#x2013;579.</Citation></Reference><Reference><Citation>Williams JA, Evans JC. An assessment of anesthetic-steroid suppositories: a controlled trial following rubber-band ligation of hemorrhoids. Dis Colon Rectum. 1972;15:66&#x2013;68.</Citation></Reference><Reference><Citation>Perrotti P, Dominici P, Grossi E, et al. Pharmacokinetics of anorectal nifedipine and lidocaine (lignocaine) ointment following haemorrhoidectomy: an open-label, single-dose, phase IV clinical study. Clin Drug Investig. 2009;29:243&#x2013;256.</Citation></Reference><Reference><Citation>Katsinelos P, Kountouras J, Paroutoglou G, et al. Aggressive treatment of acute anal fissure with 0.5% nifedipine ointment prevents its evolution to chronicity. World J Gastroenterol. 2006;12:6203&#x2013;6206.</Citation></Reference><Reference><Citation>Jonas M, Neal KR, Abercrombie JF, Scholefield JH. A randomized trial of oral vs. topical diltiazem for chronic anal fissures. Dis Colon Rectum. 2001;44:1074&#x2013;1078.</Citation></Reference><Reference><Citation>Amoli HA, Notash AY, Shahandashti FJ, Kenari AY, Ashraf H. A randomized, prospective, double-blind, placebo-controlled trial of the effect of topical diltiazem on posthaemorrhoidectomy pain. Colorectal Dis. 2011;13:328&#x2013;332.</Citation></Reference><Reference><Citation>Silverman R, Bendick PJ, Wasvary HJ. A randomized, prospective, double-blind, placebo-controlled trial of the effect of a calcium channel blocker ointment on pain after hemorrhoidectomy. Dis Colon Rectum. 2005;48:1913&#x2013;1916.</Citation></Reference><Reference><Citation>Sugimoto T, Tsunoda A, Kano N, Kashiwagura Y, Hirose K, Sasaki T. A randomized, prospective, double-blind, placebo-controlled trial of the effect of diltiazem gel on pain after hemorrhoidectomy. World J Surg. 2013;37:2454&#x2013;2457.</Citation></Reference><Reference><Citation>Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)&#x2014;a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377&#x2013;381.</Citation></Reference><Reference><Citation>Van Dijk JFM, Zaslansky R, van Boekel RLM, et al. Postoperative pain and age: a retrospective cohort association study. Anesthesiology. 2021;135:1104&#x2013;1119.</Citation></Reference><Reference><Citation>Sobrado J&#xfa;nior CW, Obregon CA, E Sousa Junior AHDS, et al. A new classification for hemorrhoidal disease: the creation of the &#x201c;BPRST&#x201d; staging and its application in clinical practice. Ann Coloproctol. 2020;36:249&#x2013;255.</Citation></Reference><Reference><Citation>Watson NF, Liptrott S, Maxwell-Armstrong CA. A prospective audit of early pain and patient satisfaction following out-patient band ligation of haemorrhoids. Ann R Coll Surg Engl. 2006;88:275&#x2013;279.</Citation></Reference><Reference><Citation>Gokalp A, Baskonus I, Maralcan G. A prospective randomised study of local anaesthetic injection after multiple rubber band ligation of haemorrhoids. Chir Ital. 2003;55:213&#x2013;217.</Citation></Reference><Reference><Citation>Shiau JM, Su HP, Chen HS, Hung KC, Lin SE, Tseng CC. Use of a topical anesthetic cream (EMLA) to reduce pain after hemorrhoidectomy. Reg Anesth Pain Med. 2008;33:30&#x2013;35.</Citation></Reference><Reference><Citation>Perrotti P, Dominici P, Grossi E, Cerutti R, Antropoli C. Topical nifedipine with lidocaine ointment versus active control for pain after hemorrhoidectomy: results of a multicentre, prospective, randomized, double-blind study. Can J Surg. 2010;53:17&#x2013;24.</Citation></Reference><Reference><Citation>Rodriguez-Wong U, Ocharan-Hernandez ME, Toscano-Garibay J. Topical diltiazem for pain after closed hemorrhoidectomy. Rev Gastroenterol Mex. 2016;81:74&#x2013;79.</Citation></Reference><Reference><Citation>Yadav S, Khandelwal RG, Om P, Ravindra K, Choudhary KL. A prospective randomized double-blind study of pain control by topical calcium channel blockers versus placebo after Milligan-Morgan hemorrhoidectomy. Int J Colorectal Dis. 2018;33:895&#x2013;899.</Citation></Reference><Reference><Citation>Mari FS, Nigri G, Dall&#x2019;Oglio A, et al. Topical glyceryl trinitrate ointment for pain related to anal hypertonia after stapled hemorrhoidopexy: a randomized controlled trial. Dis Colon Rectum. 2013;56:768&#x2013;773.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>